Clostridioides difficile resistance to antibiotics, including post-COVID-19 data

Area of Science:

• Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Clostridioides difficile infections (CDIs) pose a significant public health challenge.
• Understanding current antibiotic resistance patterns is essential for optimizing treatment strategies.

Purpose of the Study:

• To update data on Clostridioides difficile antibiotic resistance across various countries.
• To inform treatment improvements for C. difficile infections.

Main Methods:

• A systematic review and meta-analysis of C. difficile antibiotic susceptibility data from 20 countries.
• Analysis of resistance rates to vancomycin, metronidazole, moxifloxacin, clindamycin, erythromycin, rifampin, imipenem, tigecycline, and fidaxomicin.

Main Results:

• Significant variations in C. difficile antimicrobial susceptibility were observed across countries, study periods, and circulating ribotypes.
• High resistance rates were noted for moxifloxacin (34.9%) and clindamycin (61.0%), with notable variability.
• Fidaxomicin demonstrated low resistance (0-2%), while vancomycin (4.7%) and metronidazole (2.6%) showed lower mean resistance, though with wide ranges in some studies.

Conclusions:

• Regular monitoring of C. difficile antibiotic susceptibility is vital due to observed resistance variations.
• Fidaxomicin and vancomycin are recommended for CDI treatment, with metronidazole suitable for mild cases.
• Emerging therapies and ongoing surveillance are necessary to combat evolving resistance patterns.